[Form 4] BeOne Medicines Ltd. American Insider Trading Activity

Rhea-AI Filing Summary

BeOne Medicines Ltd. (ONC) director Wang Xiaodong reported a change in beneficial ownership on a Form 4 covering transactions dated 09/09/2025. The filing shows 148,096 ordinary shares were disposed of under transaction code G, reported at a price of $0, and described in the footnotes as bona fide gifts exempt from Section 16(b). After the reported transaction, the Form 4 lists 5,006,674 ordinary shares as directly beneficially owned and additional indirect holdings of 1,025,063, 3,953,100, and 50 shares held through family and trust entities, with the reporting person disclaiming beneficial ownership for certain trust-held positions. The form was signed by an attorney-in-fact on 09/11/2025.

Positive

• Transaction coded G indicating a bona fide gift, not a sale, and is exempt from Section 16(b) per the filing
• Comprehensive disclosure of direct and indirect holdings, including family trust and LLC arrangements with disclaimers

Negative

• None.

Insights

Securities Analyst

TL;DR: Director reported a gift of shares; ownership structure shows large direct and indirect holdings.

The Form 4 discloses a non‑cash disposition of 148,096 shares coded as a bona fide gift, which is treated as exempt under Rule 16b‑5. Post‑transaction holdings remain substantial at 5,006,674 shares directly and additional indirect positions totaling more than 5.9 million shares across trusts and an LLC. From a market-impact perspective, gifts do not produce immediate liquidation proceeds, but the filing clarifies concentration of ownership and related-party vehicles that affect voting and control considerations.

Corporate Governance Expert

TL;DR: Governance disclosure is complete for this transaction; trusts and LLC holdings are properly noted with disclaimers.

The submission explains the nature of indirect holdings: family trust beneficiaries, interests held by Wang Investment LLC and shares held by the reporting person's spouse, with disclaimers of beneficial ownership where appropriate. The use of an attorney‑in‑fact to sign the Form 4 is routine. The filing provides transparency on related‑party ownership but does not indicate any change in control or executive departure.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wang Xiaodong

(Last) (First) (Middle)

C/O BEONE MEDICINES I GMBH

AESCHENGRABEN 27, 21ST FLOOR

(Street)

BASEL V8 4051

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BeOne Medicines Ltd. [ ONC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Chair, Scientific Advisory Brd

3. Date of Earliest Transaction (Month/Day/Year)
09/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	09/09/2025		G		148,096	D	$0(1)	5,006,674	D
Ordinary Shares								1,025,063	I	See Footnote(2)
Ordinary Shares								3,953,100	I	See Footnote(3)
Ordinary Shares								50	I	See Footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Bona fide gift(s) of shares which are exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16b-5.

2. These securities are held by a family trust, the beneficiaries of which are the Reporting Person's family members, for which the Reporting Person disclaims beneficial ownership.

3. These securities are held by Wang Investment LLC, of which 99% of the limited liability company interest is owned by two grantor retained annuity trusts, of which the Reporting Person's wife is a trustee, for which the Reporting Person disclaims beneficial ownership.

4. These securities are held by the spouse of the Reporting Person.

Remarks:

	/s/ Qing Nian, as Attorney-in-Fact	09/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ONC director Wang Xiaodong report on the Form 4?

The filing reports a 09/09/2025 transaction where 148,096 ordinary shares were disposed of as a bona fide gift (transaction code G).

How many shares does Wang Xiaodong beneficially own after the reported transaction?

The Form 4 lists 5,006,674 shares as directly owned after the transaction, plus indirect holdings of 1,025,063, 3,953,100, and 50 shares through trusts, an LLC, and the spouse respectively.

Was the transaction a sale or did it generate cash proceeds?

No cash proceeds were reported; the disposition is recorded at $0 and described as a bona fide gift exempt from Section 16(b).

Who signed the Form 4 and when was it filed?

The form was signed by Qing Nian, as Attorney‑in‑Fact and dated 09/11/2025 on the filing.

Do the footnotes explain the nature of indirect ownership?

Yes. Footnotes state shares are held by a family trust, by Wang Investment LLC (with interests owned by grantor retained annuity trusts), and by the reporting person’s spouse, with disclaimers of beneficial ownership where specified.